aTyr Pharma, Inc.
ATYR
$3.28
$0.185.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.28% | -5.84% | -5.26% | -4.95% | -30.16% |
| Total Depreciation and Amortization | -100.26% | 1.31% | -50.26% | 89.19% | -59.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.19% | 1,862.50% | 88.06% | 70.61% | 27.62% |
| Change in Net Operating Assets | -54.65% | 179.06% | 40.49% | -315.74% | 219.04% |
| Cash from Operations | 0.20% | 35.65% | 8.63% | -102.31% | -15.72% |
| Capital Expenditure | -66.67% | -87.50% | 52.94% | 0.00% | 96.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.78% | 166.64% | 603.06% | -107.51% | 261.03% |
| Cash from Investing | -133.91% | 166.74% | 596.17% | -107.61% | 306.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.40% | -1.63% | -1.65% | -5.22% | -6.48% |
| Issuance of Common Stock | 94,735.00% | -99.85% | 72.25% | 27.68% | 120.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 18,041.90% | -100.78% | 73.35% | 28.11% | 124.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.07% | 1,558.88% | 97.99% | -225.14% | 612.83% |